Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
about
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyInterleukin-7 and interleukin-15 for cancerDeveloping Combined HIV Vaccine Strategies for a Functional CureImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteHighly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.GD2-targeted immunotherapy and radioimmunotherapyChimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodyniaProduction of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana.Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI.Identification of a gene for an ancient cytokine, interleukin 15-like, in mammals; interleukins 2 and 15 co-evolved with this third family member, all sharing binding motifs for IL-15Rα.Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Anti-GD2 immunotherapy for neuroblastoma.The potential and promise of IL-15 in immuno-oncogenic therapies.Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.Emerging classes of armed antibody therapeutics against cancer
P2860
Q26797345-826E7C3E-B706-49C5-9FB4-48DBFBFC874BQ26830709-2DC519AA-2CCB-4F1B-AFEF-8818B5750E0CQ26998898-1FDF8708-773B-4872-8E66-E4E6432161AAQ28066935-E4C06081-7CBB-444C-A4B2-70ED9B60D338Q34223872-6EE3B24E-70FB-403F-AEE3-2FC05C8BED8BQ34389202-DB908052-A3CA-425C-8F45-FBF25BDF6F9BQ34625339-1E29AE4A-BF26-4B50-B612-D518C20DA9C2Q35092616-9584FC2C-9BC7-44F8-B0A2-5CB5CCB48252Q35603066-4698E5CC-B645-4C6A-A036-0561852348C2Q37378633-F5D524BD-3687-463C-943F-2F74BC07E9F0Q37488866-95D6BA73-8D27-4E96-866F-5CB22CA52F3FQ38916529-1E3E627D-B9B4-4D12-8E4D-6F091329AE8FQ39110347-16924108-5EA6-4472-B6EE-0412FAEC2DEAQ40049630-DFDBFAE2-0449-497C-84B7-78B021952BDFQ45868734-E7E14F65-CB76-4228-A972-1C43E33B9D60Q47225780-9D2ED1ED-71DD-4652-A63D-3C1F6F0C53BEQ47277628-80726A70-30FA-41FD-8A4D-821E2F0B9CCEQ47554435-EA37B27E-4CD4-4230-95BE-ED2BAE1BD7CAQ49216382-D2AD7D82-CC1B-4DC3-BE38-608599C0D859Q51786117-636FBC7F-E793-4F6C-B804-6B25AB707AE6Q57911948-460A31FC-8EBC-4A33-86F0-EA7F85893F91
P2860
Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Tumor targeting of the IL-15 s ...... nhances its antitumor potency.
@en
Tumor targeting of the IL-15 s ...... nhances its antitumor potency.
@nl
type
label
Tumor targeting of the IL-15 s ...... nhances its antitumor potency.
@en
Tumor targeting of the IL-15 s ...... nhances its antitumor potency.
@nl
prefLabel
Tumor targeting of the IL-15 s ...... nhances its antitumor potency.
@en
Tumor targeting of the IL-15 s ...... nhances its antitumor potency.
@nl
P2093
P2860
P356
P1476
Tumor targeting of the IL-15 s ...... nhances its antitumor potency.
@en
P2093
Anne Bessard
Denis Cochonneau
Géraldine Teppaz
Marie Vincent
Mike Maillasson
Stéphane Birklé
Véronique Solé
Yannick Jacques
P2860
P304
P356
10.1002/IJC.28059
P577
2013-02-25T00:00:00Z